

# CITATION REPORT

List of articles citing

Increased plasma arginine vasopressin levels in patients with congestive heart failure

DOI: 10.1016/s0735-1097(83)80040-0

Journal of the American College of Cardiology, 1983, 1, 1385-9

**Source:** <https://exaly.com/paper-pdf/16409500/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #   | Paper  | IF   | Citations |
|-----|--|------|-----------|
| 435 | Impaired response of plasma vasopressin to orthostatic stress in patients with congestive heart failure. <i>Journal of the American College of Cardiology</i> , <b>1983</b> , 2, 1080-3  | 15.1 | 23        |
| 434 | Selective impairment of baroreflex-mediated vasoconstrictor responses in patients with ventricular dysfunction. <b>1984</b> , 69, 451-60   |      | 216       |
| 433 | Relation between serum sodium concentration and the hemodynamic and clinical responses to converting enzyme inhibition with captopril in severe heart failure. <i>Journal of the American College of Cardiology</i> , <b>1984</b> , 3, 1035-43 | 15.1 | 107       |
| 432 | Haemodynamic responses to specific renin-angiotensin inhibitors in hypertension and congestive heart failure. A review. <b>1984</b> , 28, 144-69   |      | 54        |
| 431 | Sodium, water, and congestive heart failure. <b>1984</b> , 100, 902-4  |      | 15        |
| 430 | Angiotensin II-mediated vasoconstriction in chronic congestive heart failure, and response to converting enzyme inhibition. <b>1984</b> , 77, 71-7   |      | 17        |
| 429 | Unloading the heart in congestive heart failure. <b>1984</b> , 77, 67-70   |      | 11        |
| 428 | Clinical importance of the renin-angiotensin system in chronic heart failure: double blind comparison of captopril and prazosin. <b>1985</b> , 290, 1861-5   |      | 80        |
| 427 | Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. <b>1985</b> , 103, 1-6  |      | 440       |
| 426 | The role of vasopressin in experimental and clinical hypertension. <b>1985</b> , 5, A40-7  |      | 5         |
| 425 | Response of plasma vasopressin to ethanol in congestive heart failure. <b>1985</b> , 55, 1354-7  |      | 13        |
| 424 | Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. <b>1985</b> , 55, 1043-7   |      | 82        |
| 423 | Acute effects of digoxin on total systemic vascular resistance in congestive heart failure due to dilated cardiomyopathy: a hemodynamic-hormonal study. <b>1985</b> , 56, 896-904  |      | 74        |
| 422 | Neurohumoral mechanisms involved in congestive heart failure. <b>1985</b> , 55, 15A-21A  |      | 138       |
| 421 | Pathophysiology of congestive heart failure. <b>1985</b> , 55, 9A-14A  |      | 43        |
| 420 | Arginine vasopressin and the renal response to water loading in congestive heart failure. <b>1986</b> , 58, 295-9  |      | 97        |
| 419 | Vasopressin, renin and norepinephrine levels before and after captopril administration in patients with congestive heart failure due to idiopathic dilated cardiomyopathy. <b>1986</b> , 58, 300-3   |      | 52        |

|     |  |          |
|-----|--|----------|
| 418 | Neurohumoral activation during exercise in congestive heart failure. <b>1986</b> , 81, 623-9   | 43       |
| 417 | Prostaglandins in congestive heart failure and the effects of nonsteroidal anti-inflammatory drugs. <b>1986</b> , 81, 123-32   | 29       |
| 416 | Angiotensin converting enzyme inhibitors in congestive heart failure. Overview in comparison of captopril and enalapril. <b>1986</b> , 81, 36-9  | 37       |
| 415 | Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system. <i>Journal of the American College of Cardiology</i> , <b>1986</b> , 7, 758-65 | 15.1 179 |
| 414 | Pathophysiologic relevance of neurohumoral measurements in chronic heart failure. <i>Journal of the American College of Cardiology</i> , <b>1986</b> , 7, 766-7  | 15.1 3   |
| 413 | Hemodynamic effects of infused arginine vasopressin in congestive heart failure. <i>Journal of the American College of Cardiology</i> , <b>1986</b> , 8, 779-83  | 15.1 104 |
| 412 | Reflex control of the human cardiovascular system. <b>1986</b> , 105, 1-99   | 60       |
| 411 | Endocrine mechanisms in congestive cardiac failure. Renin, aldosterone and atrial natriuretic hormone. <b>1986</b> , 32 Suppl 5, 1-12  | 15       |
| 410 | Sodium and water excretion in heart failure: efficacy of treatment has surpassed knowledge of pathophysiology. <b>1986</b> , 105, 272-4  | 6        |
| 409 | Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure. <b>1986</b> , 29, 1188-96  | 69       |
| 408 | Congestive heart failure. <b>1986</b> , 11, 301-65   | 3        |
| 407 | Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. <b>1986</b> , 73, 913-9  | 710      |
| 406 | Hormonal, global, and regional haemodynamic responses to a vascular antagonist of vasopressin in patients with congestive heart failure with and without hyponatraemia. <b>1986</b> , 56, 433-9  | 16       |
| 405 | Vasodilatation with captopril and prazosin in chronic heart failure: double blind study at rest and on exercise. <b>1986</b> , 55, 265-73  | 26       |
| 404 | Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. <b>1986</b> , 73, 257-67   | 496      |
| 403 | Acute and short-term effects of clonidine in heart failure. <b>1987</b> , 38, 537-48   | 29       |
| 402 | Enalapril: a long-acting angiotensin-converting enzyme inhibitor. <b>1987</b> , 7, 133-48  | 7        |
| 401 | Vasopressin as vasopressor. <b>1987</b> , 82, 1213-9   | 73       |

|     |   |      |     |
|-----|---|------|-----|
| 400 | Chronic renal and neurohumoral effects of the calcium entry blocker nisoldipine in patients with congestive heart failure. <i>Journal of the American College of Cardiology</i> , <b>1987</b> , 9, 622-30                 | 15.1 | 84  |
| 399 | Increase in vasoactive intestinal polypeptides (VIP) by the angiotensin converting enzyme (ACE) inhibitor lisinopril in congestive heart failure. Relation to haemodynamic and hormonal changes. <b>1987</b> , 18, 577-87 |      | 13  |
| 398 | Clinical and hemodynamic correlates of elevated plasma arginine vasopressin after acute myocardial infarction. <b>1987</b> , 60, 1178-80  |      | 34  |
| 397 | Role of nitrates in congestive heart failure. <b>1987</b> , 60, 39H-43H   |      | 9   |
| 396 | The role of neuroendocrine abnormalities in the enhanced sodium and water retention of chronic heart failure. <b>1987</b> , 61, 209-14  |      | 4   |
| 395 | Neuroendocrine manifestations of congestive heart failure. <b>1988</b> , 62, 9A-13A   |      | 36  |
| 394 | Vasodilator therapy in chronic congestive heart failure. <b>1988</b> , 62, 46A-54A  |      | 12  |
| 393 | A randomized cross-over study of enalapril in congestive heart failure: haemodynamic and hormonal effects during rest and exercise. <b>1988</b> , 34, 323-31  |      | 10  |
| 392 | Spontaneous neurohormonal fluctuation in chronic congestive heart failure. <b>1988</b> , 62, 150-1  |      | 2   |
| 391 | ACE inhibition for the failing heart: experience with captopril. <b>1988</b> , 115, 1085-93   |      | 8   |
| 390 | New trends in the use of angiotensin converting enzyme inhibitors in chronic heart failure. <b>1988</b> , 84, 36-46   |      | 6   |
| 389 | New trends in the use of angiotensin converting enzyme inhibitors in chronic heart failure. <b>1988</b> , 84, 36-46   |      | 1   |
| 388 | Congestive heart failure. <b>1988</b> , 34, 465-536   |      | 10  |
| 387 | Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. <b>1988</b> , 36, 540-600   |      | 80  |
| 386 | Variable arginine vasopressin levels in neonatal congestive heart failure. <i>Journal of the American College of Cardiology</i> , <b>1988</b> , 11, 645-50  | 15.1 | 19  |
| 385 | Neurohumoral responses to chronic myocardial infarction in rats. <b>1988</b> , 78, 376-81   |      | 103 |
| 384 | Short-term hemodynamic effects of vasopressin V1-receptor inhibition in chronic right-sided congestive heart failure. <b>1988</b> , 78, 1251-9  |      | 19  |
| 383 | Current therapy of the failing heart. <b>1988</b> , 78, 1099-107  |      | 93  |

|     |   |          |
|-----|---|----------|
| 382 | Effects of infused norepinephrine and angiotensin-II on vasopressin levels in humans. <b>1988</b> , 295, 513-6  | 10       |
| 381 | Extracardiac features of heart failure: catecholamines and hormonal changes. <b>1988</b> , 75 Suppl 1, 19-29  | 7        |
| 380 | Neurohormonal Influences in the Pathogenesis of Congestive Heart Failure. <b>1989</b> , 7, 73-86  | 14       |
| 379 | Sodium Retention in Heart Failure. <b>1989</b> , 7, 49-62   | 1        |
| 378 | Unloading the failing heart. Previous experience and future directions. <b>1989</b> , 2, 736-9  | 6        |
| 377 | Baroreflex control of renal sympathetic nerve activity is preserved in heart failure despite reduced arterial baroreceptor sensitivity. <b>1989</b> , 65, 1526-35 | 89       |
| 376 | Attenuation of the pressor response to intravenous furosemide by angiotensin converting enzyme inhibition in congestive heart failure. <b>1989</b> , 64, 1382-5   | 25       |
| 375 | Vasodilator therapy without converting-enzyme inhibition in congestive heart failure--usefulness and limitations. <b>1989</b> , 3, 375-96                         | 7        |
| 374 | The importance of thirst in maintenance of fluid balance. <b>1989</b> , 3, 371-91   | 20       |
| 373 | Pathophysiology and current therapy of congestive heart failure. <i>Journal of the American College of Cardiology</i> , <b>1989</b> , 13, 771-85                  | 15.1 119 |
| 372 | The management of heart failure and the scope for new therapies: what role for xamoterol?. <b>1989</b> , 28 Suppl 1, 59S-64S                                      |          |
| 371 | Central haemodynamic changes during lower body positive pressure in patients with congestive cardiac failure. <b>1989</b> , 23, 833-7                             | 12       |
| 370 | Angiotensin-converting enzyme inhibitors in heart failure. <b>1989</b> , 73, 315-38   | 11       |
| 369 | Arterial baroreflex abnormalities in heart failure. Reversal after orthotopic cardiac transplantation. <b>1989</b> , 79, 51-8                                     | 147      |
| 368 | Peripheral hemodynamic and humoral effects of oral zofenopril calcium (SQ. 26,991) in patients with congestive heart failure. <b>1989</b> , 29, 1077-82           | 3        |
| 367 | The effect of moderate hypotension on vasopressin levels in normal humans. <b>1989</b> , 298, 295-8   | 13       |
| 366 | Pathophysiology of vasopressin in edematous disorders. <b>1989</b> , 65, 1311-27  | 2        |
| 365 | Gamma 2-MSH in congestive heart failure: relation to atrial natriuretic peptide, arginine vasopressin and catecholamines. <b>1990</b> , 227, 183-7                | 10       |

- 364 Neuroendocrine activity in congestive heart failure. **1990**, 66, 33D-38D; discussion 38D-39D 37
- 363 Endocrinologic Warfare: The Role of Angiotensin-Converting Enzyme Inhibitors in Congestive Heart Failure. **1990**, 3, 318-331
- 362 Effects of a vasopressin antagonist with combined antipressor and antiantidiuretic activities in rats with left ventricular dysfunction. **1990**, 81, 308-11 39
- 361 Intra-cellular electrolyte changes and levels of endogenous digoxin-like substance within the plasma in patients with congestive heart failure. **1990**, 27, 47-53 18
- 360 Sustained beneficial effects of enalapril in Africans with congestive heart failure. **1990**, 29, 55-61 5
- 359 ACE inhibition improves vagal reactivity in patients with heart failure. **1990**, 120, 1120-9 67
- 358 Clinical and hemodynamic correlates of sympathetic nerve activity in normal humans and patients with heart failure: evidence from direct microneurographic recordings. *Journal of the American College of Cardiology*, **1990**, 16, 1125-34 15.1 233
- 357 Plasma levels of atrial natriuretic peptide at rest and during exercise in heart failure--influence of cardiac rhythm and haemodynamics. **1991**, 11, 183-96 13
- 356 Heart failure in 1991. **1991**, 78, 81-94 7
- 355 Reduced exercise tolerance in chronic heart failure and its relationship to neurohumoral factors. **1991**, 12 Suppl C, 21-8 29
- 354 Neuroendocrine activation in congestive heart failure. **1991**, 67, 3C-5C 13
- 353 Hemodynamic and neuroendocrine response to acute administration of the phosphodiesterase inhibitor BM14.478 in patients with congestive heart failure. **1991**, 14, 386-95 3
- 352 Carotid sinus baroreceptor reflex in dogs with experimental heart failure. **1991**, 68, 1294-301 70
- 351 A highly sensitive and rapid radioimmunoassay for the determination of arginine<sup>8</sup>-vasopressin. **1992**, 30, 229-33 1
- 350 Effects of OPC-21268, an orally effective vasopressin V1 receptor antagonist in humans. **1992**, 20, 54-8 26
- 349 Cardiac disease. **1992**, 2, 207-226 1
- 348 Role of neurohumoral control of the circulation in determining exercise capacity in patients with heart failure. **1992**, 101, 347S-349S 5
- 347 Current issues in advanced heart failure. **1992**, 76, 1057-82 1

|     |  |      |     |
|-----|--|------|-----|
| 346 | Control of sympathetic nerve activity by vagal mechanoreflexes is blunted in heart failure. <b>1992</b> , 86, 1929-34  |      | 69  |
| 345 | Is inotropic therapy for heart failure an unfulfilled promise?. <b>1992</b> , 26, 103-7  |      | 1   |
| 344 | Increased plasma concentrations of endothelin in congestive heart failure in humans. <b>1992</b> , 67, 719-24  |      | 163 |
| 343 | Baroreflex loading maneuvers do not suppress increased plasma arginine vasopressin in patients with congestive heart failure. <i>Journal of the American College of Cardiology</i> , <b>1992</b> , 19, 1180-4  | 15.1 | 20  |
| 342 | Haemodynamic and neurohumoral effects of cold pressor test in severe heart failure. <b>1992</b> , 12, 95-106   |      | 26  |
| 341 | Clinical, hemodynamic and sympathetic neural correlates of heart rate variability in congestive heart failure. <b>1992</b> , 69, 761-7   |      | 195 |
| 340 | Baroreceptor-mediated release of vasopressin in patients with chronic congestive heart failure and defective sympathetic responsiveness. <b>1992</b> , 70, 224-8   |      | 12  |
| 339 | Digitalis and baroreflexes in heart failure. <b>1992</b> , 2, 21-6   |      | 2   |
| 338 | The treatment of heart failure--what next?. <b>1993</b> , 35, 557-63   |      | 1   |
| 337 | Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. The SOLVD Investigators. <i>Journal of the American College of Cardiology</i> , <b>1993</b> , 22, 146A-153A | 15.1 | 108 |
| 336 | Abnormal baroreceptor-mediated vasodilation of the peripheral circulation in congestive heart failure secondary to idiopathic dilated cardiomyopathy. <b>1993</b> , 87, 849-56   |      | 28  |
| 335 | Hypersensitivity of inner medullary collecting duct cells to arginine vasopressin and forskolin in cardiomyopathic hamsters. <b>1993</b> , 83, 49-54   |      | 4   |
| 334 | Renal functional alterations induced by angiotensin-converting enzyme inhibitors in heart failure. <b>1993</b> , 27, 205-10  |      | 5   |
| 333 | Pharmacokinetics, safety, and pharmacologic effects of OPC-21268, a nonpeptide orally active vasopressin V1 receptor antagonist, in humans. <b>1993</b> , 33, 230-8  |      | 17  |
| 332 | Predictors of Mortality in Patients with Heart Failure. <b>1994</b> , 12, 25-35  |      | 42  |
| 331 | Physiological rationale for co-treatment with diuretics in heart failure. <b>1994</b> , 72, S63-7  |      | 4   |
| 330 | Is neurohormonal activation a major determinant of the response to ACE inhibition in left ventricular dysfunction and heart failure?. <b>1994</b> , 72, S75-80   |      | 6   |
| 329 | Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group. <b>1994</b> , 72, 422-7  |      | 41  |

|     |   |      |     |
|-----|---|------|-----|
| 328 | Evidence for impaired endothelium dependent vasodilation in experimental left ventricular dysfunction. <b>1994</b> , 21, 709-19   |      | 14  |
| 327 | Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. <i>Journal of the American College of Cardiology</i> , <b>1994</b> , 23, 1410-20 | 15.1 | 190 |
| 326 | Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. <i>Journal of the American College of Cardiology</i> , <b>1994</b> , 23, 570-8                                      | 15.1 | 249 |
| 325 | Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. <b>1994</b> , 128, 564-74  |      | 141 |
| 324 | Alterations of radial artery compliance in patients with congestive heart failure. <b>1995</b> , 76, 381-5  |      | 48  |
| 323 | Neurohumoral variability in left ventricular dysfunction. SOLVD Investigators. Studies of Left Ventricular Dysfunction. <b>1995</b> , 75, 354-9   |      | 9   |
| 322 | Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. SOLVD Investigators. <b>1995</b> , 75, 1151-7   |      | 91  |
| 321 | Modulation of vascular contractile responses to alpha 1- and alpha 2-adrenergic and neuropeptide Y receptor stimulation in rats with ischaemic heart failure. <b>1995</b> , 154, 429-37   |      | 10  |
| 320 | Electrolyte disturbances in chronic heart failure: metabolic and clinical aspects. <b>1995</b> , 18, 370-6  |      | 16  |
| 319 | Neurohormonal activation and congestive heart failure: today's experience with ACE inhibitors and rationale for their use. <b>1995</b> , 16 Suppl N, 65-72  |      | 16  |
| 318 | Improvement of cardiac performance by intravenous infusion of L-arginine in patients with moderate congestive heart failure. <i>Journal of the American College of Cardiology</i> , <b>1995</b> , 26, 1251-6  | 15.1 | 61  |
| 317 | Prognosis in congestive heart failure. <b>1996</b> , 2, S225-9  |      | 12  |
| 316 | Dietary supplementation with L-arginine fails to restore endothelial function in forearm resistance arteries of patients with severe heart failure. <i>Journal of the American College of Cardiology</i> , <b>1996</b> , 27, 1207-13  | 15.1 | 55  |
| 315 | Plasma levels of atrial natriuretic peptide and of other vasoconstricting hormones in patients with chronic heart failure: relationship to exercise capacity. <b>1996</b> , 57, 135-42  |      | 5   |
| 314 | Congestive heart failure. Towards a comprehensive treatment. <b>1996</b> , 17 Suppl B, 43-56  |      | 16  |
| 313 | Congestive heart failure in the elderly. <b>1996</b> , 23, 201-23   |      | 5   |
| 312 | Neurohumoral activation in heart failure: role of paraventricular nucleus. <b>1996</b> , 23, 722-6  |      | 42  |
| 311 | Beliefs about medication and dietary compliance in people with heart failure: an instrument development study. <b>1997</b> , 26, 273-9  |      | 55  |



|     |  |      |     |
|-----|--|------|-----|
| 310 | Reduced responsiveness of rat mesenteric resistance artery smooth muscle to phenylephrine and calcium following myocardial infarction. <b>1997</b> , 120, 1505-12  | 19   |     |
| 309 | Predicting short-term outcome in severely ill heart failure patients: implications regarding listing for urgent cardiac transplantation and patient selection for temporary ventricular assist device support. <b>1998</b> , 4, 169-75 | 7    |     |
| 308 | Anesthesia for Heart Transplantation. <b>1998</b> , 2, 131-139   | 1    |     |
| 307 | Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat. <b>1998</b> , 275, H176-82  | 10   |     |
| 306 | Renal hypersensitivity to vasopressin in congestive heart failure. <b>1998</b> , 90, 20-7  | 5    |     |
| 305 | Suppressed impact of nitric oxide on renal arteriolar function in rats with chronic heart failure. <b>1999</b> , 276, F79-87   | 10   |     |
| 304 | Enhanced acetylcholine and P2Y-receptor stimulated vascular EDHF-dilatation in congestive heart failure. <b>1999</b> , 43, 200-9   | 49   |     |
| 303 | Vasopressin: a therapeutic target in congestive heart failure?. <b>1999</b> , 5, 347-56  | 44   |     |
| 302 | Sympathetic activation in heart failure and its treatment with beta-blockade. <b>1999</b> , 159, 225-34  | 68   |     |
| 301 | Correlation between atrial natriuretic peptide and baroreflex sensitivity in patients with congestive heart failure. <b>1999</b> , 63, 893-9   | 2    |     |
| 300 | Chapter 7. Advances in the understanding and treatment of congestive heart failure (HF). <b>2000</b> , 35, 63-72   |      |     |
| 299 | Age-adjusted heart rate variability as an index of the severity and prognosis of heart failure. <b>2000</b> , 64, 32-8   | 21   |     |
| 298 | Vasopressin receptor antagonism--a therapeutic option in heart failure and hypertension. <b>2000</b> , 85 Spec No, 259S-265S   | 27   |     |
| 297 | Role of beta blockers in congestive heart failure. <b>2000</b> , 6, 299-312  | 2    |     |
| 296 | Role of paraventricular nucleus in mediating sympathetic outflow in heart failure. <i>Heart Failure Reviews</i> , <b>2000</b> , 5, 73-86   | 5    | 111 |
| 295 | Cardiac sympathetic afferent reflexes in heart failure. <i>Heart Failure Reviews</i> , <b>2000</b> , 5, 57-71  | 5    | 83  |
| 294 | Acute myocardial infarction complicated by systemic hypoperfusion without hypotension: report of the SHOCK trial registry. <b>2000</b> , 108, 374-80   |      | 127 |
| 293 | The role of thoracic ultrasonography for evaluation of patients with decompensated chronic heart failure. <i>Journal of the American College of Cardiology</i> , <b>2000</b> , 35, 1638-46   | 15.1 | 95  |

- 292 New and emerging pharmacological strategies in the management of chronic heart failure. **2001**, 1, 126-33 6
- 291 Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists. **2001**, 10, 825-34 13
- 290 Enhanced Ca<sup>2+</sup>-induced contractions and attenuated alpha-adrenoceptor responses in resistance arteries from rats with congestive heart failure. **2001**, 3, 7-13 4
- 289 The role of ANG II and endothelin-1 in exercise-induced diastolic dysfunction in heart failure. **2001**, 280, H1853-60 34
- 288 Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives. **2001**, 21, 661-72 95
- 287 Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. **2001**, 104, 2417-23 295
- 286 Moderate alcohol consumption and risk of heart failure among older persons. **2001**, 285, 1971-7 154
- 285 Left ventricle and arteries: structure, function, hormones, and disease. **2001**, 37, 346-9 15
- 284 Vasopressin antagonists in CHF: ready for clinical trials?. **2002**, 54, 13-5 10
- 283 Vasopressin-induced presynaptic facilitation of sympathetic neurotransmission in the pithed rat. **2002**, 20, 1175-80 9
- 282 Chronic vasopressin V(1A) but not V(2) receptor antagonism prevents heart failure in chronically infarcted rats. **2002**, 449, 135-41 8
- 281 Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction. **2002**, 450, 169-77 21
- 280 Congestive heart failure: potential role of arginine vasopressin antagonists in the therapy of heart failure. **2002**, 8, 251-6 29
- 279 Vasopressin-induced facilitation of adrenergic responses in the rat mesenteric artery is V1-receptor dependent. **2003**, 23, 35-41 3
- 278 Vasopressin: a new target for the treatment of heart failure. **2003**, 146, 9-18 171
- 277 The role of arginine vasopressin and its receptors in the normal and failing rat heart. **2003**, 35, 495-504 25
- 276 Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization. **2003**, 145, S3-17 59
- 275 Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. **2003**, 107, 2690-6 369

|     |  |     |
|-----|--|-----|
| 274 | Vasopressin receptor antagonists. Therapeutic potential in the management of acute and chronic heart failure. <b>2003</b> , 3, 13-20                             | 11  |
| 273 | Endothelium-dependent, vasopressin-induced contractions in rabbit renal arteries. <b>2003</b> , 42, 703-9  | 6   |
| 272 | Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. <b>2004</b> , 291, 1963-71 | 511 |
| 271 | Vasopressin receptor antagonists: will the "vaptans" fulfill their promise?. <b>2004</b> , 291, 2017-8   | 20  |
| 270 | Risk factors and outcomes for Oasoplegia syndrome following cardiac transplantation. <b>2004</b> , 25, 327-32  | 60  |
| 269 | Basal and exercise-induced neuroendocrine activation in patients with heart failure and in normal subjects. <b>2004</b> , 6, 29-39                               | 31  |
| 268 | Urinary excretion of aquaporin-2 water channel exaggerated dependent upon vasopressin in congestive heart failure. <b>2004</b> , 66, 1387-92                     | 50  |
| 267 | Vasopressin antagonists in heart failure. <b>2004</b> , 1, 190-6   | 3   |
| 266 | Neuroendocrine evaluation of cardiac disease. <b>2004</b> , 34, 1105-26  | 51  |
| 265 | Endothelin upregulates the expression of vasopressin V2 mRNA in the inner medullary collecting duct of the rat. <b>2004</b> , 53, 1177-83                        | 5   |
| 264 | Regulation of arginine vasopressin in the human heart. <b>2005</b> , 69, 1401-4  | 6   |
| 263 | Neurohormonal activation in congestive heart failure and the role of vasopressin. <b>2005</b> , 95, 8B-13B   | 200 |
| 262 | Pharmacology of new agents for acute heart failure syndromes. <b>2005</b> , 96, 68G-73G  | 49  |
| 261 | Hyponatremia in patients with heart failure. <b>2005</b> , 96, 19L-23L   | 149 |
| 260 | Overview of vasopressin receptor antagonists in heart failure resulting in hospitalization. <b>2005</b> , 96, 24L-33L  | 136 |
| 259 | Novel therapies for heart failure: vasopressin and selective aldosterone antagonists. <b>2005</b> , 11, 21-9   | 5   |
| 258 | Hyponatremia and heart failure--pathophysiology and implications. <b>2005</b> , 11, 274-7  | 50  |
| 257 | Role of vasopressin antagonists in the management of acute decompensated heart failure. <b>2005</b> , 2, 131-9   | 4   |

|     |   |         |
|-----|---|---------|
| 256 | Effects of nNOS antisense in the paraventricular nucleus on blood pressure and heart rate in rats with heart failure. <b>2005</b> , 288, H205-13  | 36      |
| 255 | Vasopressin, cortisol, and catecholamine concentrations in dogs with dilated cardiomyopathy. <b>2005</b> , 66, 1709-17  | 14      |
| 254 | Novel neurohormonal antagonist strategies: vasopressin antagonism, anticytokine therapy, and endothelin antagonism in patients who have heart failure. <b>2005</b> , 1, 103-27  | 1       |
| 253 | Vasopressin receptor antagonists in the management of acute heart failure. <b>2005</b> , 14, 593-600  | 4       |
| 252 | Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. <b>2005</b> , 111, 2454-60 | 376     |
| 251 | Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). <b>2005</b> , 11, 260-9  | 154     |
| 250 | Vasopressin antagonism in heart failure. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 46, 1785-91   | 151 188 |
| 249 | Conivaptan: a selective vasopressin antagonist for the treatment of heart failure. <b>2006</b> , 4, 17-23   | 6       |
| 248 | The Pathophysiologic Basis of Nuclear Medicine. <b>2006</b> ,   | 14      |
| 247 | Decreased wheel-running activity in hamsters post myocardial infarction. <b>2006</b> , 4, 51  |         |
| 246 | Possible vascular role of increased plasma arginine vasopressin in congestive heart failure. <b>2006</b> , 106, 191-5   | 62      |
| 245 | Effects of long-term oral treatment with selective vasopressin V2 receptor antagonist (OPC-31260) on adriamycin-induced heart failure in rats. <b>2006</b> , 108, 231-6   | 6       |
| 244 | . <b>2006</b> ,   | 1       |
| 243 | The Role of Vasopressin and Vasopressin Antagonists in Heart Failure. 187-204   |         |
| 242 | Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. <b>2006</b> , 36, 771-8  | 166     |
| 241 | Treating hyponatremia in heart failure. <b>2006</b> , 8, 204-10   | 3       |
| 240 | Neurohormonal modulation in heart failure of ischemic etiology: correlates with left ventricular remodeling. <b>2006</b> , 3, 157-63  | 4       |
| 239 | Hyponatremia and heart failure--treatment considerations. <b>2006</b> , 12, 55-60   | 22      |

|     |  |          |
|-----|--|----------|
| 238 | Neurohumoral changes in patients with left ventricular dysfunction following acute myocardial infarction and the effect of nitrate therapy: a randomized, double-blind, placebo-controlled long-term study. <b>2006</b> , 48, 166-72   | 6        |
| 237 | Vasopressin receptor antagonists in heart failure. <b>2006</b> , 1, 177-84   | 4        |
| 236 | Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. <b>2006</b> , 290, F273-8   | 206      |
| 235 | Treatment of Advanced Heart Disease. <b>2006</b> ,   | 1        |
| 234 | An L-RNA-based aquaretic agent that inhibits vasopressin in vivo. <b>2006</b> , 103, 5173-8  | 43       |
| 233 | Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure. <b>2006</b> , 15, 533-40  | 9        |
| 232 | Emerging drugs for acute and chronic heart failure: current and future developments. <b>2007</b> , 12, 75-95   | 4        |
| 231 | Functional arginine vasopressin system in early heart maturation. <b>2007</b> , 293, H2262-70  | 22       |
| 230 | Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. <b>2007</b> , 297, 1319-31  | 1118     |
| 229 | Vasopressin-induced vasoconstriction: two concentration-dependent signaling pathways. <b>2007</b> , 102, 1402-9  | 55       |
| 228 | Effect of exercise training on autonomic derangement and neurohumoral activation in chronic heart failure. <b>2007</b> , 13, 294-303   | 81       |
| 227 | Arginine vasopressin increases iNOS-NO system activity in cardiac fibroblasts through NF-kappaB activation and its relation with myocardial fibrosis. <b>2007</b> , 81, 327-35   | 35       |
| 226 | Vasopressin dysregulation: hyponatremia, fluid retention and congestive heart failure. <b>2007</b> , 120, 1-9  | 27       |
| 225 | Vasopressin antagonists in the management of heart failure. <b>2007</b> , 5, 323-30  | 3        |
| 224 | Therapeutic potential of vasopressin receptor antagonists. <b>2007</b> , 67, 847-58  | 85       |
| 223 | Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 49, 2151-9 | 15.1 133 |
| 222 | Heart Failure. 137-165   |          |
| 221 | . <b>2007</b> ,  | 2        |

|     |  |          |
|-----|--|----------|
| 220 | Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]. <b>2007</b> , 25, 261-79  | 26       |
| 219 | Hyponatremia and vasopressin antagonism in congestive heart failure. <b>2007</b> , 30, 546-51  | 23       |
| 218 | Pharmacological characterization of RWJ-676070, a dual vasopressin V(1A)/V(2) receptor antagonist. <b>2008</b> , 590, 333-42   | 9        |
| 217 | Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 52, 1540-5 | 15.1 145 |
| 216 | Acute Heart Failure. <b>2008</b> ,   | 7        |
| 215 | Mechanisms, risks, and new treatment options for hyponatremia. <b>2008</b> , 111, 147-57   | 44       |
| 214 | Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. <b>2008</b> , 14, 641-7   | 85       |
| 213 | C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction. <b>2008</b> , 14, 739-45   | 87       |
| 212 | Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. <b>2008</b> , 118, 410-21  | 83       |
| 211 | Effects of novel vasopressin receptor antagonists on renal function and cardiac hypertrophy in rats with experimental congestive heart failure. <b>2008</b> , 326, 414-22  | 17       |
| 210 | Tolvaptan: the evidence for its therapeutic value in acute heart failure syndrome. <b>2008</b> ,   |          |
| 209 | Tolvaptan and its potential in the treatment of hyponatremia. <b>2008</b> , 4, 1149-55   | 22       |
| 208 | Conivaptan: Evidence supporting its therapeutic use in hyponatremia. <b>2010</b> , 4, 83-92  | 15       |
| 207 | Novel biomarkers in heart failure: an overview. <b>2009</b> , 3, 453-63  | 7        |
| 206 | Emerging diuretics for the treatment of heart failure. <b>2009</b> , 14, 195-204   | 3        |
| 205 | C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. <b>2009</b> , 30, 1187-94   | 173      |
| 204 | AMP-activated protein kinase influences metabolic remodeling in H9c2 cells hypertrophied by arginine vasopressin. <b>2009</b> , 296, H1822-32  | 17       |
| 203 | Changes of renal AQP2, ENaC, and NHE3 in experimentally induced heart failure: response to angiotensin II AT1 receptor blockade. <b>2009</b> , 297, F1678-88   | 38       |

202 Congestive heart failure secondary to ischemic heart disease. **1986**, 712, 65-71

201 PATHOPHYSIOLOGIC ASPECTS - HEMODYNAMICS. **2009**, 219, 7-14

200 Nervous system control mechanisms in heart failure. **1986**, 707, 15-20 3

199 The renin system and atrial natriuretic hormone in congestive heart failure. **1986**, 707, 45-53 4

198 Treatment options for hyponatremia in heart failure. *Heart Failure Reviews*, **2009**, 14, 65-73 5 11

197 Salt and water balance in congestive heart failure. **1986**, 707, 27-31 4

196 Pharmacological treatment of chronic systolic heart failure: are we scraping the bottom of the barrel?. **2010**, 11, 893-905 3

195 Hyponatremia-induced osteoporosis. **2010**, 25, 554-63 274

194 Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure. *Heart Failure Reviews*, **2010**, 15, 85-101 5 30

193 Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents. **2010**, 15, 826-41 29

192 Treatment options for hyponatremia in heart failure. **2010**, 16 Suppl 1, S15-8 2

191 Pathophysiology of Volume Overload in Acute Heart Failure Syndromes. **2010**, 16, S1-S6 7

190 Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study. **2010**, 3, 249-53 29

189 Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure. **2010**, 3, 412-9 21

188 Pathophysiology of fluid retention in heart failure. **2010**, 164, 46-53 24

187 The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. **2010**, 12, 338-47 116

186 Cardiorenal syndrome: new perspectives. **2010**, 121, 2592-600 343

185 The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists. **2010**, 16, 419-31 34

|     |   |         |
|-----|---|---------|
| 184 | The association between alcohol consumption and morbidity and mortality in patients undergoing coronary artery bypass surgery. <b>2010</b> , 24, 580-5  | 10      |
| 183 | Tolvaptan for the treatment of heart failure: a review of the literature. <b>2011</b> , 12, 961-76  | 35      |
| 182 | Biomonitoring and biomarker-guided therapy: the next step in heart failure and biomarker research. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 58, 1890-2  | 15.1 36 |
| 181 | A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction. <b>2011</b> , 17, 973-81 | 73      |
| 180 | Management of Volume Overload in Heart Failure. <b>2011</b> , 650-658   |         |
| 179 | Hyponatremia and arginine vasopressin in early stage of ST-elevation acute myocardial infarction. -Surrogate markers or therapeutic targets?-. <b>2011</b> , 75, 1823-4   |         |
| 178 | Early development of hyponatremia implicates short- and long-term outcomes in ST-elevation acute myocardial infarction. <b>2011</b> , 75, 1927-33   | 21      |
| 177 | Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH). <b>2011</b> , 67, 333-346      | 35      |
| 176 | Targeting hyponatremia and hemodynamics in acute decompensated heart failure: is there a role for vasopressin antagonists?. <b>2011</b> , 8, 198-205  | 12      |
| 175 | Hyponatraemia and vasopressin in heart failure: markers or mediators?. <b>2011</b> , 13, 242-4  | 6       |
| 174 | Prevalence and prognostic significance of hyponatraemia in outpatients with chronic heart failure. <b>2011</b> , 13, 968-73   | 49      |
| 173 | Impact of change in serum sodium concentration on mortality in patients hospitalized with heart failure and hyponatremia. <b>2011</b> , 4, 637-43   | 45      |
| 172 | Aortocaval fistula in rat: a unique model of volume-overload congestive heart failure and cardiac hypertrophy. <b>2011</b> , 2011, 729497   | 58      |
| 171 | Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study. <b>2011</b> , 4, 613-20  | 141     |
| 170 | Inhibitory-excitatory synaptic balance is shifted toward increased excitation in magnocellular neurosecretory cells of heart failure rats. <b>2011</b> , 106, 1545-57   | 31      |
| 169 | Altered astrocyte glutamate transporter regulation of hypothalamic neurosecretory neurons in heart failure rats. <b>2012</b> , 303, R291-300  | 37      |
| 168 | Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure. <b>2012</b> , 5, 484-92  | 38      |
| 167 | Central angiotensin type 1 receptor blockade decreases cardiac but not renal sympathetic nerve activity in heart failure. <b>2012</b> , 59, 634-41  | 32      |



|     |   |   |    |
|-----|---|---|----|
| 166 | Neurohumoral stimulation. <b>2012</b> , 8, 87-99  |   | 81 |
| 165 | Copeptin in the assessment of acute lung injury and cardiogenic pulmonary edema. <b>2012</b> , 106, 1268-77   |   | 18 |
| 164 | Function of the hypothalamo-neurohypophysial system in rats with myocardial infarction is modified by melatonin. <b>2012</b> , 64, 1442-54  |   | 13 |
| 163 | Can we prevent or treat renal dysfunction in acute heart failure?. <i>Heart Failure Reviews</i> , <b>2012</b> , 17, 291-303   |   | 14 |
| 162 | Perspectives for the treatment of anemia in heart failure: is there a role for vasopressin antagonists?. <b>2012</b> , 18, 1-3  |   | 2  |
| 161 | Significance of hyponatremia in heart failure. <i>Heart Failure Reviews</i> , <b>2012</b> , 17, 17-26   | 5 | 34 |
| 160 | Tolvaptan increases serum sodium in pediatric patients with heart failure. <b>2013</b> , 34, 1463-8   |   | 26 |
| 159 | Acute heart failure: patient characteristics and pathophysiology. <b>2013</b> , 10, 427-33  |   | 21 |
| 158 | New and emerging biomarkers in left ventricular systolic dysfunction--insight into dilated cardiomyopathy. <b>2013</b> , 6, 516-27  |   | 24 |
| 157 | Hyponatremia. <b>2013</b> ,   |   | 2  |
| 156 | Hyponatraemia: more than just a marker of disease severity?. <b>2013</b> , 9, 37-50   |   | 64 |
| 155 | Cardiorenal syndrome: pathophysiology and potential targets for clinical management. <b>2013</b> , 9, 99-111  |   | 99 |
| 154 | Hyponatremia in Heart Failure. <b>2013</b> , 127-143  |   |    |
| 153 | Enhanced NMDA receptor-mediated intracellular calcium signaling in magnocellular neurosecretory neurons in heart failure rats. <b>2013</b> , 305, R414-22   |   | 15 |
| 152 | Copeptin: a new marker in cardiology. <b>2013</b> , 14, 19-25   |   | 21 |
| 151 | Tolvaptan for the treatment of hyponatremia and hypervolemia in patients with congestive heart failure. <b>2013</b> , 9, 163-76   |   | 7  |
| 150 | Validation of a commercially available enzyme immunoassay for measurement of plasma antidiuretic hormone concentration in healthy dogs and assessment of plasma antidiuretic hormone concentration in dogs with congestive heart failure. <b>2013</b> , 74, 1206-11 |   | 6  |
| 149 | Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. <b>2013</b> , 6, 47-52   |   | 56 |

|     |  |         |
|-----|--|---------|
| 148 | Hyponatremia in patients with heart failure. <b>2013</b> , 5, 317-28   | 43      |
| 147 | Neurohypophyseal hormones: novel actors of striated muscle development and homeostasis. <b>2014</b> , 24,  | 14      |
| 146 | Copeptin as a biomarker in heart failure. <b>2014</b> , 8, 841-54  | 25      |
| 145 | Emerging biomarkers for acute heart conditions. <b>2014</b> , 29, 312-8  | 13      |
| 144 | Cardiac effects of vasopressin. <b>2014</b> , 64, 100-7  | 15      |
| 143 | Association of hyponatremia to diuretic response and incidence of increased serum creatinine levels in hospitalized patients with acute decompensated heart failure. <b>2014</b> , 128, 333-42 | 6       |
| 142 | Management of cardiorenal metabolic syndrome in diabetes mellitus: a phytotherapeutic perspective. <b>2014</b> , 2014, 313718  | 9       |
| 141 | Increased vasopressin 1A receptor expression in failing human hearts. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 375-6   | 15.1 15 |
| 140 | Can the difference in serum concentration of urea and cystatin C be used in diagnosis and prognosis of heart failure?. <b>2014</b> , 83, 401-3   | 2       |
| 139 | Time and technology will tell: the pathophysiologic basis of neurohormonal modulation in heart failure. <b>2014</b> , 10, 543-57   | 14      |
| 138 | Potential roles of vaptans in heart failure: experience from clinical trials and considerations for optimizing therapy in target patients. <b>2014</b> , 10, 607-20                            | 6       |
| 137 | Plasma vasopressin levels in patients with right-sided heart dysfunction and chronic thromboembolic pulmonary hypertension (CTEPH). <b>2014</b> , 28, 601-7                                    |         |
| 136 | Therapeutic potential of vasopressin-receptor antagonists in heart failure. <b>2014</b> , 124, 1-6   | 33      |
| 135 | The interplay between sympathetic overactivity, hypertension and heart rate variability (review, invited). <b>2014</b> , 101, 129-42   | 8       |
| 134 | Low cardiac output stimulates vasopressin release in patients with stage d heart failure. <b>2014</b> , 78, 2259-67  | 45      |
| 133 | Awareness of the vasopressin system in heart failure. <b>2014</b> , 78, 2157-8   | 1       |
| 132 | Neuroendocrine-autonomic integration in the paraventricular nucleus: novel roles for dendritically released neuropeptides. <b>2015</b> , 27, 487-97  | 35      |
| 131 | Hyponatremia Associated with Heart Failure: Pathological Role of Vasopressin-Dependent Impaired Water Excretion. <b>2015</b> , 4, 933-47   | 12      |

|     |   |      |    |
|-----|---|------|----|
| 130 | Effects of Qili Qiangxin Capsule on AQP2, V2R, and AT1R in Rats with Chronic Heart Failure. <b>2015</b> , 2015, 639450  |      | 10 |
| 129 | The secretion patterns and roles of cardiac and circulating arginine vasopressin during the development of heart failure. <b>2015</b> , 51, 63-73   |      | 13 |
| 128 | The pathophysiological role of interstitial sodium in heart failure. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 378-388   | 15.1 | 78 |
| 127 | Hyponatremia in acute decompensated heart failure: depletion versus dilution. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 480-92   | 15.1 | 91 |
| 126 | Prognostic Role of Serum Chloride Levels in Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 659-66  | 15.1 | 83 |
| 125 | Left ventricular vs. biventricular mechanical support: Decision making and strategies for avoidance of right heart failure after left ventricular assist device implantation. <b>2015</b> , 198, 241-50 |      | 52 |
| 124 | Thirst in chronic heart failure: a review. <b>2015</b> , 24, 916-26   |      | 15 |
| 123 | Pathophysiology of Heart Failure and an Overview of Therapies. <b>2016</b> , 271-339  |      | 1  |
| 122 | Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure. <b>2016</b> , 17,                                 |      | 14 |
| 121 | Copeptin in Heart Failure. <b>2016</b> , 73, 29-64  |      | 14 |
| 120 | Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction. <b>2017</b> , 243, 79-108   |      | 4  |
| 119 | Elevation of arginine vasopressin levels following loop diuretic therapy as a prognostic indicator in heart failure. <b>2016</b> , 44, 1430-1442  |      | 6  |
| 118 | Decongestion: more than meets the eye!. <b>2016</b> , 18, 192-4   |      | 3  |
| 117 | Danhong injection attenuates cardiac injury induced by ischemic and reperfused neuronal cells through regulating arginine vasopressin expression and secretion. <b>2016</b> , 1642, 516-523             |      | 16 |
| 116 | Pharmacologic Approaches to Electrolyte Abnormalities in Heart Failure. <b>2016</b> , 13, 181-9   |      | 13 |
| 115 | Importance of Abnormal Chloride Homeostasis in Stable Chronic Heart Failure. <b>2016</b> , 9, e002453   |      | 45 |
| 114 | A Functional Coupling Between Carbon Monoxide and Nitric Oxide Contributes to Increased Vasopressin Neuronal Activity in Heart Failure rats. <b>2016</b> , 157, 2052-66                                 |      | 8  |
| 113 | Arginine vasopressin receptor signaling and functional outcomes in heart failure. <b>2016</b> , 28, 224-233   |      | 28 |

|     |  |       |
|-----|--|-------|
| 112 | Serum Chloride and Sodium Interplay in Patients With Acute Myocardial Infarction and Heart Failure With Reduced Ejection Fraction: An Analysis From the High-Risk Myocardial Infarction Database Initiative. <b>2017</b> , 10, | 28    |
| 111 | Vasopressin and Vasopressin Antagonists in Heart Failure. <b>2017</b> , 243, 307-328   | 6     |
| 110 | Heart Failure. <b>2017</b> ,   | 4     |
| 109 | The evolution of heart failure with reduced ejection fraction pharmacotherapy: What do we have and where are we going?. <b>2017</b> , 178, 67-82   | 2     |
| 108 | A reduction in SK channels contributes to increased activity of hypothalamic magnocellular neurons during heart failure. <b>2017</b> , 595, 6429-6442  | 12    |
| 107 | Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study. <b>2017</b> , 46, 417-426                       | 8     |
| 106 | Prognostic importance of sodium level trajectory in acute heart failure. <i>Heart and Vessels</i> , <b>2017</b> , 32, 1498-1505  | 5     |
| 105 | Integration of renal sensory afferents at the level of the paraventricular nucleus dictating sympathetic outflow. <b>2017</b> , 204, 57-64   | 28    |
| 104 | Implications of Serum Chloride Homeostasis in Acute Heart Failure (from ROSE-AHF). <b>2017</b> , 119, 78-83  | 26    |
| 103 | Application of Nucleic Acid Aptamers in Polypeptides Researches. <b>2017</b> , 45, 1795-1803   | 1     |
| 102 | Is Exaggerated Release of Arginine Vasopressin an Endocrine Disorder? Pathophysiology and Treatment. <b>2017</b> , 6,  | 3     |
| 101 | Comparison of the Effects of Carperitide and Tolvaptan on Patients with Left Ventricular Dysfunction: A Two-Center Retrospective Study. <b>2017</b> , 2017, 6935342  | 1     |
| 100 | Cardioskeletal Myopathies in Congenital Heart Diseases. <b>2017</b> , 347-357  |       |
| 99  | A metabolomics study of Qiliqiangxin in a rat model of heart failure: a reverse pharmacology approach. <b>2018</b> , 8, 3688   | 2     |
| 98  | Serum chloride as a novel marker for adding prognostic information of mortality in chronic heart failure. <b>2018</b> , 483, 112-118   | 13    |
| 97  | The relationship between the time until commencement of tolvaptan and the length of hospital stay in heart failure patients. <i>Heart and Vessels</i> , <b>2018</b> , 33, 367-373  | 2.1 9 |
| 96  | Hemodynamic effects of short-term infusion of a vasopressin V1A/V2 receptor antagonist conivaptan in patients with chronic heart failure during submaximal exercise. <b>2018</b> , 203, 101-104                                | 2     |
| 95  | Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT. <b>2018</b> , 20, 1436-1443   | 17    |

|    |  |       |
|----|--|-------|
| 94 | Serial Change in Serum Chloride During Hospitalization Could Predict Heart Failure Death in Acute Decompensated Heart Failure Patients. <b>2018</b> , 82, 1041-1050                                      | 20    |
| 93 | Combined Evaluation of the Plasma Arginine Vasopressin and Noradrenaline Levels May be a Useful Predictor of the Prognosis of Patients with Acute Decompensated Heart Failure. <b>2018</b> , 59, 791-801 | 7     |
| 92 | Diuretic Resistance in Cardio-Nephrology: Role of Pharmacokinetics, Hypochloremia, and Kidney Remodeling. <b>2019</b> , 44, 915-927  | 10    |
| 91 | Arginine vasopressin modulates electrical activity and calcium homeostasis in pulmonary vein cardiomyocytes. <b>2019</b> , 26, 71  | 4     |
| 90 | Hypervolemic Hyponatremia in Heart Failure. <b>2019</b> , 52, 113-129  | 2     |
| 89 | Arginine vasopressin antagonism in heart failure: Current status and possible new directions. <b>2019</b> , 74, 49-52  | 5     |
| 88 | Hyponatremia and metabolic bone disease in patients with epilepsy: A cross-sectional study. <b>2019</b> , 123, 67-75   | 6     |
| 87 | Renal Mechanisms and Heart Failure. <b>2019</b> , 101-121  |       |
| 86 | The historical evolution of knowledge of the involvement of neurohormonal systems in the pathophysiology and treatment of heart failure. <b>2019</b> , 38, 883-895                                       |       |
| 85 | The historical evolution of knowledge of the involvement of neurohormonal systems in the pathophysiology and treatment of heart failure. <b>2019</b> , 38, 883-895                                       | 2     |
| 84 | Acute myocardial infarction activates magnocellular vasopressin and oxytocin neurones. <b>2019</b> , 31, e12808  | 4     |
| 83 | Relationship between non-osmotic arginine vasopressin secretion and hemoglobin A1c levels in adult patients with congenital heart disease. <i>Heart and Vessels</i> , <b>2019</b> , 34, 809-814          | 2.1 1 |
| 82 | Hemodynamic and Hormonal Effects of Tolvaptan for Heart Failure. <b>2019</b> , 58, 471-475   | 4     |
| 81 | Hyponatraemia in heart failure. <b>2020</b> , 50, 659-666  | 1     |
| 80 | Highly sensitive and selective colorimetric detection of arginine by polyvinylpyrrolidone functionalized silver nanoparticles. <b>2020</b> , 300, 112361   | 14    |
| 79 | Pathophysiology of Diuretic Resistance and Its Implications for the Management of Chronic Heart Failure. <b>2020</b> , 76, 1045-1054   | 11    |
| 78 | Diabetes prevalence and outcomes in hospitalized cardiorenal-syndrome patients with and without hyponatremia. <b>2020</b> , 21, 393  | 0     |
| 77 | The role of oxytocin and vasopressin in the pathophysiology of heart failure in pregnancy and in fetal and neonatal life. <b>2020</b> , 318, H639-H651   | 8     |

|    |  |    |   |
|----|--|----|---|
| 76 | Severe Hyponatraemia Associated with the Use of Arginine-Vasopressin in Two Neonates with Complex Congenital Heart Disease. <b>2020</b> , 9, 213-215                                 | 1  |   |
| 75 | Differential role of specific cardiovascular neuropeptides in pain regulation: Relevance to cardiovascular diseases. <b>2020</b> , 81, 102046  | 4  |   |
| 74 | Somato-dendritic vasopressin and oxytocin secretion in endocrine and autonomic regulation. <b>2020</b> , 32, e12856  | 21 |   |
| 73 | Functional coupling between NMDA receptors and SK channels in rat hypothalamic magnocellular neurons: altered mechanisms during heart failure. <b>2021</b> , 599, 507-520            | 4  |   |
| 72 | Vasopressin antagonism in heart failure: a review of the hemodynamic studies and major clinical trials. <b>2021</b> , 15, 1753944720977741   | 7  |   |
| 71 | The Biology of Vasopressin. <b>2021</b> , 9,   | 10 |   |
| 70 | Aquaporins and diseases pathogenesis: From trivial to undeniable involvements, a disease-based point of view. <b>2021</b> , 236, 6115-6135   | 1  |   |
| 69 | Copeptin is associated with mortality in elderly people. <b>2021</b> , 51, e13516  | 0  |   |
| 68 | Neuroprotective Effect of Aurantio-Obtusin, a Putative Vasopressin V Receptor Antagonist, on Transient Forebrain Ischemia Mice Model. <b>2021</b> , 22,                              | 0  |   |
| 67 | Serum sodium and eplerenone use in patients with a myocardial infarction and left ventricular dysfunction or heart failure: insights from the EPHEUS trial. <b>2021</b> , 1          | 0  |   |
| 66 | Arginine Vasopressin as an Important Mediator of Fluctuations in the Serum Creatinine Concentration Under Decongestion Treatment in Heart Failure Patients. <b>2021</b> , 3, 324-332 | 1  |   |
| 65 | Copeptin as a predictive marker of incident heart failure. <b>2021</b> , 8, 3180-3188  | 7  |   |
| 64 | Current and emerging drug targets in heart failure treatment. <i>Heart Failure Reviews</i> , <b>2021</b> , 1   | 5  | 4 |
| 63 | Cardiorenal Syndrome: An Important Subject in Nephrocardiology. <b>2021</b> , 39, 455-469  | 3  |   |
| 62 | Therapeutics in Congestive Heart Failure: From Hemodynamics to Neurohormones. <b>2003</b> , 17-34  | 2  |   |
| 61 | Prognosis in Congestive Heart Failure. <b>1994</b> , 622-627   | 10 |   |
| 60 | Recent advances in the understanding of water metabolism in heart failure. <b>1998</b> , 449, 415-26   | 34 |   |
| 59 | Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers. <b>1998</b> , 449, 455-65   | 13 |   |

|    |  |     |
|----|--|-----|
| 58 | Pathophysiology and Clinical Recognition of Heart Failure. <b>2007</b> , 1379-1396   | 1   |
| 57 | Hyponatremia in the Setting of Acute Heart Failure Syndrome. <b>2008</b> , 786-796   | 2   |
| 56 | Cardiac and Baroreflex Control of the Circulation in Heart Failure. <b>1991</b> , 45-55  | 2   |
| 55 | Neurohumoral Aspects of Heart Failure. <b>1994</b> , 12, 9-23  | 27  |
| 54 | Trauma in Patients with Pre-Existing Cardiac Disease. <b>1994</b> , 10, 461-506  | 7   |
| 53 | Neurohumoral mechanisms in heart failure: a central role for the renin-angiotensin system. <b>1996</b> , 27 Suppl 2, S1-8  | 19  |
| 52 | Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats. <b>1996</b> , 27, 275-82                 | 38  |
| 51 | Coronary arterial hyperreactivity and mesenteric arterial hyporeactivity after myocardial infarction in the rat. <b>1997</b> , 29, 780-8                                     | 19  |
| 50 | Effects of arginine vasopressin on differentiation of cardiac fibroblasts into myofibroblasts. <b>2010</b> , 55, 489-95  | 14  |
| 49 | Functional coupling between NMDA receptors and SK channels in rat hypothalamic magnocellular neurons: altered mechanisms during heart failure.                               | 2   |
| 48 | Short-term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure. <b>1996</b> , 94, 779-84  | 44  |
| 47 | Arginine vasopressin increases nitric oxide synthesis in cytokine-stimulated rat cardiac myocytes. <b>1997</b> , 30, 1112-20   | 20  |
| 46 | Vasopressin-mediated forearm vasodilation in normal humans. Evidence for a vascular vasopressin V2 receptor. <b>1989</b> , 84, 418-26  | 95  |
| 45 | Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. <b>1993</b> , 92, 2653-9   | 108 |
| 44 | Prognostic Impact of Early Changes in Serum Chloride Concentrations Among Hospitalized Acute Heart Failure Patients - A Retrospective Cohort Study. <b>2020</b> , 2, 409-419 | 2   |
| 43 | Cardiorenal Syndrome: Role of Arginine Vasopressin and Vaptans in Heart Failure. <b>2017</b> , 8, 87-95  | 23  |
| 42 | Novel Biomarkers in Cardiovascular Disease: A Review. <b>2010</b> , 2, 66  | 1   |
| 41 | Tolvaptan: the evidence for its therapeutic value in acute heart failure syndrome. <b>2008</b> , 3, 31-43  | 2   |

- 40 Neurohypophyseal Hormones: Novel Actors of Striated Muscle Development and Homeostasis. **2014**, 24, 3790 19
- 39 Arginine vasopressin as a target in the treatment of acute heart failure. **2014**, 6, 1252-61 11
- 38 Initial experience with conivaptan use in critically ill infants with cardiac disease. **2012**, 17, 78-83 6
- 37 Complementary Role of Oxytocin and Vasopressin in Cardiovascular Regulation. **2021**, 22, 5
- 36 The Role of Neurohormonal Systems, Inflammatory Mediators and Oxydative Stress in Cardiomyopathy. 0
- 35 Neurohormones in Advanced Heart Failure. **2000**, 3-23
- 34 Vasopressin antagonists. **2005**, 521-544
- 33 Acute Heart Failure. *Fundamental and Clinical Cardiology*, **2006**, 203-226
- 32 Vasopressin Antagonists in Acute Heart Failure Syndromes. **2008**, 621-625
- 31 Diuretics. **2011**, 1879-1916
- 30 Herzinsuffizienz. *Verhandlungen Der Deutschen Gesellschaft Fur Innere Medizin*, **1985**, 115-180
- 29 Mechanisms of Vasoconstriction in Hypertension and Chronic Congestive Heart Failure. *Developments in Cardiovascular Medicine*, **1987**, 143-150
- 28 Vasopressin in Patients with Liver and Cardiac Disease. **1987**, 209-214
- 27 Vasodilator Therapy for Cardiomyopathy. **1990**, 428-434
- 26 Direct Measurement of Aortic and Vena Caval Flow to Evaluate the Effect of Vasodilators in Experimental Acute mitral regurgitation. **1990**, 91-100
- 25 Pharmacological Intervention In The Failing Heart. **1990**, 99-112 0
- 24 Congestive Heart Failure. **1991**, 101-114
- 23 Neurohumoral Mechanisms in Chronic Heart Failure. **1991**, 221-240



|    |   |     |   |
|----|---|-----|---|
| 22 | Congestive Heart Failure: Acute and Chronic. <b>1992</b> , 365-381  |     |   |
| 21 | Effect of medications on cardiac output. <i>Developments in Cardiovascular Medicine</i> , <b>1993</b> , 225-250   |     |   |
| 20 | Mechanisms of Deficient cAMP Generation in Heart Failure. <b>1993</b> , 120-131   |     | 1 |
| 19 | The Peripheral Circulation in Heart Failure. <b>1994</b> , 145-160  |     | 2 |
| 18 | Nonadrenergic Hormonal Alterations in Congestive Heart Failure. <b>1994</b> , 136-144   |     |   |
| 17 | Medical Treatment of Heart Failure: Problems in Dilated Cardiomyopathy. <b>1998</b> , 229-235   |     |   |
| 16 | Nuclear Cardiology 2: Myocardial Perfusion, Metabolism, Infarction, and Receptor Imaging. <b>2015</b> , 463-528   |     |   |
| 15 | CORRELATION BETWEEN VAS OPRESSIN CONCENTRATION AND CHRONIC HEART FAILURE SEVE RITY: CHARAC TERISTICS OF PA TIENTS WITH TERMINAL AND DECOMPE NSA TED HEART FAILURE. <i>Klinicist</i> , <b>2018</b> , 12, 36-42 | 0.3 |   |
| 14 | CORRELATION OF SERUM CHLORIDE LEVELS WITH 30 DAY MORTALITY IN HEART FAILURE PATIENTS. <i>Journal of Evidence Based Medicine and Healthcare</i> , <b>2019</b> , 6, 1849-1853                                   | 0   |   |
| 13 | A Multi-Gene Synaptic Plasticity Array Identifies Candidate Molecular Underpinnings of Cognitive and Mood Deficits in Rats with Heart Failure.  |     |   |
| 12 | Copeptin as a marker of atherosclerosis and arteriosclerosis. <i>Atherosclerosis</i> , <b>2021</b> , 338, 64-68   | 3.1 | 1 |
| 11 | Basis of Cardiac Imaging 2: Myocardial Perfusion, Metabolism, Infarction, and Receptor Imaging in Coronary Artery Disease and Congestive Heart Failure. <b>2006</b> , 352-394                                 |     |   |
| 10 | Sodium-based osmotherapy for hyponatremia in acute decompensated heart failure. <i>Heart Failure Reviews</i> , <b>2021</b> , 1  | 5   | 1 |
| 9  | Metoprolol Protects Against Arginine Vasopressin-Induced Cellular Senescence in H9C2 Cardiomyocytes by Regulating the Sirt1/p53/p21 Axis. <i>Cardiovascular Toxicology</i> , <b>2021</b> , 22, 99             | 3.4 | 0 |
| 8  | Relationships between sodium levels, haemodynamics and metalloproteinases in heart failure patients.. <i>Heart and Vessels</i> , <b>2022</b> , 1  | 2.1 |   |
| 7  | Pathophysiology of heart failure and an overview of therapies. <b>2022</b> , 149-221  |     |   |
| 6  | Copeptin as a Diagnostic and Prognostic Biomarker in Cardiovascular Diseases. <i>Frontiers in Cardiovascular Medicine</i> , 9,  | 5.4 | 0 |
| 5  | Neuroendocrine hormone status and diuretic response to atrial natriuretic peptide in patients with acute heart failure.   |     | 0 |

- 4 Vasopressin: a possible link between hypoxia and hypertension. 414-431 ○
- 3 Involvement of Vasopressin in Tissue Hypoperfusion during Cardiogenic Shock Complicating Acute Myocardial Infarction in Rats. **2023**, 24, 1325 ○
- 2 Trajectory of serum chloride levels during decongestive therapy in acute heart failure. **2022**, ○
- 1 Serum Chloride and Heart Failure. **2023**, 5, 100614 ○